Immuno-PET and Targeted {alpha}-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma

Conclusion: [89Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, and targeted α-therapy using [211At]GPC1 mAb showed tumor growth suppression. GPC1 is a promising target for future applications for the precise diagnosis of pancreatic ductal adenocarcinoma and GPC1-targeted theranostics.

Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Watabe, T., Kabayama, K., Naka, S., Yamamoto, R., Kaneda, K., Serada, S., Ooe, K., Toyoshima, A., Wang, Y., Haba, H., Kurimoto, K., Kobayashi, T., Shimosegawa, E., Tomiyama, N., Fukase, K., Naka, T. Tags: Basic Science Investigations Source Type: research